440 related articles for article (PubMed ID: 28154088)
1. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients.
Engelhardt M; Domm AS; Dold SM; Ihorst G; Reinhardt H; Zober A; Hieke S; Baayen C; Müller SJ; Einsele H; Sonneveld P; Landgren O; Schumacher M; Wäsch R
Haematologica; 2017 May; 102(5):910-921. PubMed ID: 28154088
[TBL] [Abstract][Full Text] [Related]
2. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores.
Engelhardt M; Dold SM; Ihorst G; Zober A; Möller M; Reinhardt H; Hieke S; Schumacher M; Wäsch R
Haematologica; 2016 Sep; 101(9):1110-9. PubMed ID: 27479825
[TBL] [Abstract][Full Text] [Related]
3. Validation of the Freiburg Comorbidity Index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome.
Kleber M; Ihorst G; Gross B; Koch B; Reinhardt H; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):541-51. PubMed ID: 23810244
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the prognostic significance of 5 comorbidity scores and 12 functional tests in a prospective multiple myeloma patient cohort.
Scheubeck S; Ihorst G; Schoeller K; Holler M; Möller MD; Reinhardt H; Wäsch R; Engelhardt M
Cancer; 2021 Sep; 127(18):3422-3436. PubMed ID: 34061991
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Frailty Scores in Newly Diagnosed Patients with Multiple Myeloma: A Review.
Mian H; Brouwers M; Kouroukis CT; Wildes TM
J Frailty Aging; 2019; 8(4):215-221. PubMed ID: 31637409
[TBL] [Abstract][Full Text] [Related]
6. Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Kleber M; Ihorst G; Udi J; Koch B; Wäsch R; Engelhardt M
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):38-48. PubMed ID: 22054851
[TBL] [Abstract][Full Text] [Related]
7. Elderly patients with multiple myeloma: towards a frailty approach?
Zweegman S; Engelhardt M; Larocca A;
Curr Opin Oncol; 2017 Sep; 29(5):315-321. PubMed ID: 28763310
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma.
Kim SM; Kim MJ; Jung HA; Kim K; Kim SJ; Jang JH; Kim WS; Jung CW
Biomed Res Int; 2014; 2014():437852. PubMed ID: 25114902
[TBL] [Abstract][Full Text] [Related]
9. Development of a new clinical index to easily assess frailty of elderly patients with multiple myeloma in Asian population.
Lee HS; Lee J; Jo JC; Jung SH; Lee JJ; Kim D; Lee S; Song K
Sci Rep; 2021 Nov; 11(1):22907. PubMed ID: 34824362
[TBL] [Abstract][Full Text] [Related]
10. Geriatric Assessment to Predict Survival and Risk of Serious Adverse Events in Elderly Newly Diagnosed Multiple Myeloma Patients: A Multicenter Study in China.
Zhong YP; Zhang YZ; Liao AJ; Li SX; Tian C; Lu J
Chin Med J (Engl); 2017 Jan; 130(2):130-134. PubMed ID: 28091402
[TBL] [Abstract][Full Text] [Related]
11. Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma.
Mian HS; Wildes TM; Fiala MA
JCO Clin Cancer Inform; 2018; 2():. PubMed ID: 30547157
[TBL] [Abstract][Full Text] [Related]
12. Prognostic effect of comorbidity indices in elderly patients with multiple myeloma.
Bila J; Jelicic J; Djurasinovic V; Vukovic V; Sretenovic A; Andjelic B; Antic D; Todorovic M; Mihaljevic B
Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):416-9. PubMed ID: 25873436
[TBL] [Abstract][Full Text] [Related]
13. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
14. Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older.
Murillo A; Cronin AM; Laubach JP; Hshieh TT; Tanasijevic AM; Richardson PG; Driver JA; Abel GA
J Geriatr Oncol; 2019 May; 10(3):486-489. PubMed ID: 30472368
[TBL] [Abstract][Full Text] [Related]
15. A comparison of three different approaches to defining frailty in older patients with multiple myeloma.
Isaacs A; Fiala M; Tuchman S; Wildes TM
J Geriatr Oncol; 2020 Mar; 11(2):311-315. PubMed ID: 31326393
[TBL] [Abstract][Full Text] [Related]
16. The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population-based study.
Gregersen H; Vangsted AJ; Abildgaard N; Andersen NF; Pedersen RS; Frølund UC; Helleberg C; Broch B; Pedersen PT; Gimsing P; Klausen TW
Cancer Med; 2017 Jul; 6(7):1807-1816. PubMed ID: 28639741
[TBL] [Abstract][Full Text] [Related]
17. A new clinically applicable age-specific comorbidity index for preoperative risk assessment of ovarian cancer patients.
Noer MC; Sperling CD; Antonsen SL; Ottesen B; Christensen IJ; Høgdall C
Gynecol Oncol; 2016 Jun; 141(3):471-478. PubMed ID: 27056103
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty.
Murugappan MN; King-Kallimanis BL; Bhatnagar V; Kanapuru B; Farley JF; Seifert RD; Stenehjem DD; Chen TY; Horodniceanu EG; Kluetz PG
J Geriatr Oncol; 2024 Mar; 15(2):101681. PubMed ID: 38104480
[TBL] [Abstract][Full Text] [Related]
19. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
20. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
